The David Rubenstein Show Dave Ricks
Jan 9, 2025
Dave Ricks, CEO of Eli Lilly, leads the pharmaceutical giant known for its revolutionary anti-obesity drugs. In this insightful conversation, he reveals plans to explore how weight-loss medications might address addictive behaviors. Ricks also tackles the pressing issue of counterfeit drugs and discusses healthcare affordability, stressing that many families shy away from medical care due to costs. His personal journey from Indiana to leading innovation in healthcare highlights the importance of tackling health challenges with creativity and resolve.
AI Snips
Chapters
Transcript
Episode notes
GLP-1 and Weight Loss Discovery
- Eli Lilly launched its first GLP-1 medication for diabetes in 2005.
- A patient featured on their annual report the following year noted weight loss as a side effect.
Similar Drugs, Different Indications
- Novo Nordisk and Eli Lilly offer similar drugs for diabetes and obesity.
- The drugs for each condition are essentially the same, with the distinction made primarily for insurance reasons.
How GLP-1 Drugs Work
- GLP-1 medications boost signals of fullness and nutrient absorption.
- Eli Lilly's Mounjaro utilizes both GLP-1 and GIP, while Ozempic only uses GLP-1.